2360O The double antibody drug conjugate (DAD) phase I trial: Sacituzumab govitecan (SG) plus enfortumab vedotin (EV) as ≥ second-line therapy for metastatic urothelial carcinoma (mUC)
Bradley A. McGregor(Harvard University), Joaquim Bellmunt(Dana-Farber Cancer Institute), Praful Ravi(Dana-Farber Cancer Institute), Lucia Kwak(Harvard University), Xiao X. Wei(Dana-Farber Cancer Institute), Guru Sonpavde(AdventHealth Orlando), Toni K. Choueiri(Harvard University), J.E. Berchuck(Brigham and Women's Hospital), M. Dror Michaelson(Harvard University), Xīn Gào(Qingdao University), Charlene Mantia(Dana-Farber Cancer Institute)
Cited by 4
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k